Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting


This study is ongoing, but not recruiting participants.
National Heart, Lung, and Blood Institute (NHLBI)
St. Jude Medical
Northwestern University
Information provided by (Responsible Party):
Christine M. Albert, MD, MPH, Brigham and Women's Hospital Identifier:
First received: April 29, 2010
Last updated: March 30, 2016
Last verified: March 2016
This is a prospective, multi-center cohort study of patients with a history of coronary artery disease (CAD) and documentation of either a prior myocardial infarction (MI) or mild to moderate left ventricular dysfunction (LVEF 35-50%). The primary objective of this study is to identify a series of markers that alone or in combination specifically predict risk of arrhythmic death as compared to other causes of mortality among this at risk population of coronary heart disease (CHD) patients with preserved left ventricular ejection fraction (LVEF> 35%). In addition, we will also address whether promising genetic markers and biomarkers advance sudden cardiac death (SCD) risk prediction when combined with advanced substrate imaging by participants that have undergone a contrast enhanced (CE) MRI at baseline.

Coronary Artery Disease
Left Ventricular Dysfunction
Sudden Cardiac Death

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: PRE-DETERMINE: Biologic Markers and MRI SCD Cohort Study

Further study details as provided by Brigham and Women's Hospital:

Primary Outcome Measures:
  • To identify a series of genetic markers and biomarkers that specifically predict risk of arrhythmic death as compared to other causes of mortality among CAD patients with preserved left ventricular ejection fraction (LVEF > 35%). [ Time Frame: Once an adequate number of sudden arrhythmic events (~n=400) has accrued a nested case-cohort design will be utilized to test for associations between biomarkers and sudden arrhythmic events. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To determine whether these genetic markers and biomarkers advance SCD risk prediction when combined with advanced substrate imaging by CE-MRI. [ Time Frame: Once an adequate number of sudden arrhythmic events (~n=400) has accrued a nested case-cohort design will be utilized to test for associations between genetic variants and sudden arrhythmic events. ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA
plasma, buffy coat, and red blood cells

Enrollment: 5763
Study Start Date: June 2007
Estimated Study Completion Date: February 2017
Estimated Primary Completion Date: February 2017 (Final data collection date for primary outcome measure)
Detailed Description:

There are an estimated 250,000-400,000 sudden cardiac deaths (SCD) annually in the United States constituting approximately 50% of all cardiac deaths. Although clinical trials have demonstrated convincing survival benefits conferred by implantable cardioverter defibrillator (ICD) therapy in selected patients with left ventricular ejection fractions (LVEF) less than 35% and congestive heart failure, the overwhelming majority of patients who suffer a cardiac arrest will have an LVEF> 0.35. The PRE-DETERMINE: Biologic Markers and MRI SCD Cohort Study seeks to identify patients at a substantially higher risk of arrhythmic death among coronary heart disease (CHD) patients with preserved left ventricular ejection fractions (LVEF>35%). If biomarkers or genetic markers are identified that can specifically predict risk of ventricular arrhythmias, then these markers may serve as relatively inexpensive methods to identify those at risk. The public health impact of identifying markers could be quite substantial, leading to more efficient utilization of ICDs and advances in our understanding of mechanisms underlying SCD.

The PRE-DETERMINE Study is a prospective, multi-center study of patients with a history of coronary artery disease (CAD) and documentation of either a prior myocardial infarction (MI) or mild to moderate left ventricular dysfunction (LVEF 35-50%). Patients will be enrolled at about 100 sites where information on baseline demographic, clinical characteristics, pertinent past medical history, lifestyle habits, and medications will be collected. Electrocardiograms along with a blood sample will also be collected at baseline, sent to central laboratories, and stored for future analyses. The participants contact information will be collected and stored in a secure database and all participants will be followed centrally on a 6-month basis via mail/phone to document interim non-fatal arrhythmic events and cause-specific mortality. Study endpoints will be confirmed through review of medical records, interviews with next-of-kin, death certificates, and autopsy reports, if available.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Participants will be recruited throughout multicenter sites participating in the PRE-DETERMINE Cohort Study. We plan to enroll patients with a history of coronary artery disease and documentation of either a prior myocardial infarction (MI) or mild to moderate left ventricular dysfunction (LVEF 35-50%). The clinical study staff at each site, which may be a research nurse, fellow, or physician will approach eligible patients to discuss their potential participation.

Inclusion Criteria

  1. Evidence of Coronary Artery Disease (CAD) a or documented prior Myocardial Infarction.
  2. LVEF >35% by any current standard evaluation technique (e.g.,) echocardiogram, MUGA, angiography). 2.1. Patients who have an LVEF between 30-35% and NYHA Class I heart failure who do not have history of ventricular tachyarrhythmias,or inducible ventricular tachycardia during electrophysiological (EP) testing can be enrolled.
  3. If documented prior MI is not present, evidence of mild-moderate systolic Left Ventricular Dysfunction with an EF >35- ≤50% as measured by any current standard screening technique (e.g.,echocardiogram, MUGA, angiography) must be present.
  4. Patients aged 18 years or above

    1. CAD will be defined as evidence of one of the following two (2) criteria:

      • Significant stenosis of a major epicardial vessel (>50% proximal or 70% distal) by coronary angiography
      • Prior revascularization (percutaneous coronary intervention or coronary artery bypass surgery)
    2. MI can be documented in the following ways:

      • From the MI hospitalization: Detection of a rise and fall of cardiac biomarkers > 99th percentile of lab (e.g., CPK elevation or Troponin at least > two times the upper limit of normal) together with myocardial ischemia with at least one of the following:

        • Symptoms of Ischemia
        • ECG changes indicative of new ischemia (new ST-T changes or new LBBB)
        • Development of pathological Q waves
        • Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality
      • If no report from the MI hospitalization is available, prior MI can be met by either of the following:

        • Development of pathological Q waves
        • Imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence of a non-ischaemic cause

Exclusion Criteria

  1. History of cardiac arrest or spontaneous or inducible sustained VT (15 beats or more at a rate of 120 BPM or greater - the occurrence of cardiac arrest or spontaneous VT in the setting of an acute MI is not considered an exclusion).
  2. Unexplained syncope
  3. Current or planned implantable cardiac defibrillator (ICD)
  4. Any condition other than cardiac disease that, in the investigator's judgment, would seriously limit life expectancy (poor survival)
  5. Metastatic cancer
  6. Marked valvular heart disease requiring surgical intervention
  7. Current or planned cardiac, renal or liver transplant
  8. Current alcohol or drug abuse
  9. Unwilling or unable to provide informed consent
  10. LVEF <35% with Class II-III CHF or LVEF <30%
  11. Participation in a clinical trial where the active treatment arm is testing an agent and/or intervention with known antiarrhythmic properties
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01114269

  Hide Study Locations
United States, Alaska
Alaska Heart Institute
Anchorage, Alaska, United States, 99508
United States, Arizona
Phoenix Heart, PLLC
Glendale, Arizona, United States, 85306
Cardiovascular Consultants
Phoenix, Arizona, United States, 85032
United States, California
Beaver Medical Group/Clinical Care Research
Banning, California, United States, 92220
United States, Colorado
Memorial Health System
Colorado Springs, Colorado, United States, 80909
Colorado Heart and Vascular
Denver, Colorado, United States, 80204
United States, Florida
Bay Area Cardiology Associates, P.A.
Brandon, Florida, United States, 33511
University of Florida - Gainsville
Gainesville, Florida, United States, 32610
Mount Sinai Medical Center
Miami Beach, Florida, United States, 33140
Reliable Clinical Research
Miami, Florida, United States, 33135
Florida Hospital
Orlando, Florida, United States, 32804
Orlando Regional Medical Center
Orlando, Florida, United States, 32806
Palm Beach Gardens Research Center
Palm Beach Gardens, Florida, United States, 33410
Velella Research
Sarasota, Florida, United States, 34233
Tallahassee Research Institute, Inc.
Tallahassee, Florida, United States, 32308
Cardiology Associates of Palm Beach - West Palm Beach
West Palm Beach, Florida, United States, 33401
United States, Georgia
Georgia Heart Specialist
Covington, Georgia, United States, 30014
Northeast Georgia Heart Center, P.C.
Gainesville, Georgia, United States, 30501
United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60637
Advocate Medical Group
Chicago, Illinois, United States, 60643
Advocate Medical Group - Heart and Vascular of IL
Chicago, Illinois, United States, 60657
Consultants in Cardiovascular Medicine
Melrose Park, Illinois, United States, 60160
United States, Indiana
Community Heart and Vascular
Anderson, Indiana, United States, 46011
United States, Iowa
Iowa Heart Center
West Des Moines, Iowa, United States, 50266
United States, Kansas
The University of Kansas
Kansas City, Kansas, United States, 66160
United States, Kentucky
Baptist Health Lexington
Lexington, Kentucky, United States, 40503
United States, Louisiana
Leonard J. Chabert Medical Center
Houma, Louisiana, United States, 70363
United States, Maine
Maine Research Associates
Auburn, Maine, United States, 04210
Maine Research Associates - Lewiston
Lewiston, Maine, United States, 04240
United States, Maryland
University of Maryland Medical Center
Baltimore, Maryland, United States, 21201
United States, Massachusetts
Primary Care Cardiology Research
Ayer, Massachusetts, United States, 01432
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
NECCR Internal Medicine and Cardiology Associates, LLC
Fall River, Massachusetts, United States, 02720
Hawthorn Medical Associates
North Dartmouth, Massachusetts, United States, 02747
Baystate Cardiology
Springfield, Massachusetts, United States, 01199
United States, Michigan
University of Michigan Medical Center
Ann Arbor, Michigan, United States, 48109
Oakwood Hospital & Medical Center
Dearborn, Michigan, United States, 48124
McLaren Medical Center - Macomb
Mt. Clemens, Michigan, United States, 48043
Michigan Heart
Ypsilanti, Michigan, United States, 48197
United States, Minnesota
Minneapolis VA Medical Center
Minneapolis, Minnesota, United States, 55417
United States, Missouri
University of Missouri Health Care
Columbia, Missouri, United States, 65201
United States, Montana
Glacier View Cardiology
Kalispell, Montana, United States, 59901
United States, Nebraska
The Cardiac Center of Creighton University
Omaha, Nebraska, United States, 68131
United States, New Jersey
Advanced Heartcare, LLC
Bridgewater, New Jersey, United States, 08807
St. Joseph Regional Medical Center
Paterson, New Jersey, United States, 07503
United States, New Mexico
New Mexico VA Healthcare Systems
Albuquerque, New Mexico, United States, 87108
United States, New York
Albany Associates Cardiology
Albany, New York, United States, 12205
Maimonides Medical Center
Brooklyn, New York, United States, 11219
Buffalo General Hospital/Kaleida Health
Buffalo, New York, United States, 14203
Jamaica Hospital Medical Center
Jamaica, New York, United States, 11418
Mid-Valley Cardiology
Kingston, New York, United States, 12401
Winthrop-University Hospital
Mineola, New York, United States, 11501
Gotham Cardiovascular
New York, New York, United States, 10001
Columbia University Health Center
New York, New York, United States, 10032
Stony Brook University Medical Center
Stony Brook, New York, United States, 11794
St. Elizabeth Medical Center - Hotvedt
Utica, New York, United States, 13501
United States, North Carolina
Asheville Cardiology Associates
Asheville, North Carolina, United States, 28801
Eastern Carolina Cardiovascular
Elizabeth City, North Carolina, United States, 27909
Northstate Clinical Research
Lenoir, North Carolina, United States, 28645
Pinehurst Medical Clinic, Inc.
Pinehurst, North Carolina, United States, 28374
Sanford Cardiology
Sanford, North Carolina, United States, 27330
Wake Forest
Winston-Salem, North Carolina, United States, 27157
United States, Ohio
Northeast Ohio Cardiovascular Specialists
Akron, Ohio, United States, 44304
University of Cincinnati
Cincinnati, Ohio, United States, 45267
MetroHealth Medical Center
Cleveland, Ohio, United States, 44109
North Ohio Research, Ltd.
Elyria, Ohio, United States, 44035
Mercy Medical Associates
Fairfield, Ohio, United States, 45014
Northwest Ohio Cardiology Consultants/The Toledo Hospital
Toledo, Ohio, United States, 43615
United States, Oklahoma
Oklahoma City VA Medical Center Veterans Research and Education Foundation
Oklahoma City, Oklahoma, United States, 73104
Oklahoma Foundation for Cardiovascular Research
Oklahoma City, Oklahoma, United States, 73120
United States, Pennsylvania
Abington Memorial Hospital
Abington, Pennsylvania, United States, 19001
St. Luke's Bethlehem
Bethlehem, Pennsylvania, United States, 18018
Doylestown Cardiology Associates
Doylestown, Pennsylvania, United States, 18901
Allegheny General Hospital
Pittsburgh, Pennsylvania, United States, 15212
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213
United States, South Carolina
AnMed Health
Anderson, South Carolina, United States, 29621
VA Medical Center - Charleston
Charleston, South Carolina, United States, 29425
Carolina Cardiology Associates
Rock Hill, South Carolina, United States, 29732
United States, South Dakota
Black Hills Cardiovascular Research
Rapid City, South Dakota, United States, 57701
United States, Tennessee
Cardiovasular Research of Knoxville
Knoxville, Tennessee, United States, 37917
Memphis VA Medical Center
Memphis, Tennessee, United States, 38104
United States, Texas
St. Luke's Episcopal Hospital
Houston, Texas, United States, 77030
Non-Invasive Cardiovascular PA
Houston, Texas, United States, 77074
Providence Health Center
Waco, Texas, United States, 76712
United States, Utah
Intermountain Medical Center
Murray, Utah, United States, 84157
United States, Virginia
Cardiovascular Associates Virginia Beach
Virginia Beach, Virginia, United States, 23454
Canada, Alberta
University of Alberta
Edmonton, Alberta, Canada, T6G 2B7
Canada, British Columbia
Vancouver General Hospital
Vancouver, British Columbia, Canada, V5Z 1M9
Canada, Ontario
Mississauga Clinical Research Centre
Mississauga, Ontario, Canada, L5B 2P7
Puerto Rico
Transcatheter Medical, Inc. Centro Cardiovascular de Caguas y del Caribe
Rio Piedras, Puerto Rico, 00924
Sponsors and Collaborators
Brigham and Women's Hospital
National Heart, Lung, and Blood Institute (NHLBI)
St. Jude Medical
Northwestern University
Principal Investigator: Christine M Albert, MD, MPH Brigham and Women's Hospital
  More Information

Additional Information:
Responsible Party: Christine M. Albert, MD, MPH, Principal Investigator, Brigham and Women's Hospital Identifier: NCT01114269     History of Changes
Other Study ID Numbers: 2007-P-000840, 3041108  R01HL091069 
Study First Received: April 29, 2010
Last Updated: March 30, 2016
Health Authority: United States: Institutional Review Board

Keywords provided by Brigham and Women's Hospital:
Coronary Artery Disease
Sudden Cardiac Death
Myocardial Infarction
Percutaneous coronary intervention
Implantable Cardiac Defibrillator

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Ventricular Dysfunction
Ventricular Dysfunction, Left
Death, Sudden, Cardiac
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Pathologic Processes
Heart Arrest
Death, Sudden processed this record on December 02, 2016